predictors and impact of non-adherence in adults with attention-deficithyperactivity disorder receiving oros methylphenidate results from a randomized, placebo-controlled trial预测和影响缺乏依从性在成人attention-deficithyperactivity患者接受奥罗斯哌醋甲酯结果随机、安慰剂对照试验.pdfVIP

Kooij et al. BMC Psychiatry 2013, 13:36 /1471-244X/13/36 RESEARCH ARTICLE Open Access Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial 1* 2 3 4 5 J J Sandra Kooij , Michael Rösler , Alexandra Philipsen , Sandra Wächter , Joachim Dejonckheere , 6 6 7 Annemarie van der Kolk , Michel van Agthoven and Barbara Schäuble Abstract Background: Medication non-adherence has an important impact on treatment efficacy and healthcare burden across a range of conditions and therapeutic areas. The aim of this analysis was to determine predictors of non-adherence and impact of non-adherence on treatment response in adults with attention-deficit/hyperactivity disorder (ADHD). Methods: Post-hoc analysis of a 13-week randomized, double-blind placebo-controlled study of OROS methylphenidate (MPH) 54 and 72 mg/day. Primary efficacy variable was the Conners’ Adult ADHD Rating Scale – Screening Version (CAARS:O-SV). Daily adherence was calculated as average daily adherence (100 × capsules taken/2), with overall adherence calculated as the average daily adherence. Predictors of adherence were assessed using mixed-effects logistic regression. Descriptive statistics were generated for change in CAARS:O-SV score for adherent ( 95% adherence) and non-adherent subjects. Predictors of change were analyzed using a mixed model. Results: Subjects were allocated to OROS MPH (54 mg, n = 87; 72 mg, n = 92) or placebo (n = 97). Mean adherence was 92.6% and 93.3% (OROS MPH 54 and 72 mg/day, respectively), versus 97.5